Recent Trends of Helicobacter pylori Eradication Therapy in Korea |
Yun Kyeong Kim, Joon Sung Kim, Byung Wook Kim |
Division of Gastroenterology, Incheon St. Mary's Hospital, Department of Internal Medicine, The Catholic University of Korea, College of Medicine, Incheon, Korea. gastro@catholic.ac.kr |
헬리코박터 제균 치료의 현재와 미래-국내의 제균 치료 현황 |
김윤경, 김준성, 김병욱 |
가톨릭대학교 의과대학 내과학교실 인천성모병원 소화기내과 |
|
Abstract |
Helicobacter pylori infection is one of the most common gastrointestinal infectious diseases in Korea and is related to diseases such as gastritis, peptic ulcer disease, marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type, and gastric adenocarcinoma. The eradication of H. pylori infection requires combinations of antibiotics and acid suppressants. Triple therapy has been considered as the first-line therapy for a long time. However, its eradication rate is declining and we need more effective strategies. Quadruple therapy including acid suppressants, bismuth, and other two antibiotics is a main rescue therapy after first-line therapy failure in Korea. In this review, we describe new therapeutic regimens and new trends of H. pylori eradication in Korea. |
Key Words:
Helicobacter pylori; Eradication |
|